Hunan Er-Kang Pharmaceutical Co.Ltd(300267) april 28 disclosed the first quarterly report of 2022. In the first quarter, the company realized an operating revenue of 426 million yuan, a year-on-year increase of 11.09%; The net profit attributable to the shareholders of the listed company was 225336 million yuan, down from the same period last year.
The company said that the growth of operating revenue in the first quarter of 2022 was mainly due to the growth of sales of auxiliary materials and overseas pharmaceutical intermediates; Affected by the epidemic, the logistics in some areas was blocked, and the sales structure of products was affected, resulting in a decrease in gross profit margin and net profit year-on-year in the reporting period.
It is noteworthy that among the top ten shareholders disclosed in the first quarterly report, Hunan Jinyang Investment Group Co., Ltd. is a new state-owned legal person shareholder, with a shareholding ratio of 1.39%, ranking fifth. In addition, among the top ten shareholders, Hong Kong Central Clearing Co., Ltd. continued to increase its holdings.
It was established in November 1999 as a wholly-owned enterprise invested by the people’s Government of Liuyang district and directly under the jurisdiction of Hunan Jinyang Economic Development Group Co., Ltd.
